Ulcerative Colitis

A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study Evaluating the Efficacy and Safety of JNJ-54781532 in Subjects with Moderately to Severely Active Ulcerative Colitis.

Register Today!

Trial Information

Start DateCompleted
Trial Duration32 weeks
Number of Visits12
Lead CRCMarija Bernstein
End DateTBD

For additional information
on this trial contact: